Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-0501: Doublet vs Monotherapy in Elderly NSCLC
NCT00298415Phase 3Completed
- Sponsor
- IFCT
- Start
- Mar 2006
- Primary completion
- Sep 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Overall Survival at 1 year. Started Mar 2006; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00298415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298415.